AnTolRx is revolutionizing the treatment of autoimmune diseases through the development of novel, targeted therapeutics utilizing specific self-antigens and unique tolerogenic molecules to actively promote immune tolerance. Our patented nanotechnology is designed induce antigen specific immune tolerance.
Our nanoparticles incorporate three integral aspects which work together to send a strong therapeutic signal:
- Signal 1 : Antigen
The antigen is the target of our tolerogenic signal and can be a protein, peptide, or collection of peptides. With the versatility of our nanoparticle system, this component can be customized to target antigens relevant to any autoimmune disease.
- Signal 2 : Tolerance Molecule
The tolerogenic molecule is designed to induce a strong anti-inflammatory signal and promote tolerance to our desired antigen. Such molecules include ligands of the aryl hydrocarbon receptor (AHR) which induces immune tolerance through the induction of anti-inflammatory pathways and the suppression of pro-inflammatory signals.
- Signal 3 : PEG (polyethylene glycol) Coating
An external layer which attracts a shell of water and increases both the half life and the transport speed of the nanoparticle, to ensure the most reliable and effective delivery of our tolerogenic signal.
We are rapidly advancing a potential therapy for the treatment of Type 1 Diabetes through partnerships with Pfizer, Inc. and JDRF and are advancing pre-clinical programs in a number of other auto-immune related diseases, including Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Celiac Disease, Myasthenia Gravis, and Multiple Sclerosis.